Company Overview - CG Oncology, Inc. (CGON) is expected to report flat earnings compared to the previous year, with a projected quarterly loss of $0.36 per share, indicating no change from the year-ago quarter [3][10] - Revenues are anticipated to be $0.6 million, reflecting a 13.2% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Zacks Earnings ESP for CG Oncology is -21.30%, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [10][11] Historical Performance - In the last reported quarter, CG Oncology was expected to post a loss of $0.41 per share but actually reported a loss of $0.48, resulting in a surprise of -17.07% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Comparison with Industry Peers - Stoke Therapeutics, Inc. (STOK), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.37 per share, which represents a year-over-year change of +35.1% [17] - Stoke Therapeutics has an Earnings ESP of 32.43% and a Zacks Rank of 2 (Buy), indicating a higher likelihood of beating the consensus EPS estimate [18]

Wall Street expects a year-over-year increase in earnings on higher revenues when Stoke Therapeutics, Inc. (STOK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Company Performance - Stoke Therapeutics reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.55 per share a year ago, representing an earnings surprise of 9.62% [1] - The company posted revenues of $4.89 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 41.65%, compared to revenues of $3.31 million in the same quarter last year [2] - Over the last four quarters, Stoke Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Stoke Therapeutics shares have increased approximately 149.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 19.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.56 on revenues of $2.96 million, and for the current fiscal year, it is -$2.10 on revenues of $14.82 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Stoke Therapeutics belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-38938 Stoke Therapeutics, Inc. (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR Not applicable (Former name, former address and former fiscal year, if chan ...